Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

Inotuzumab ozogamicin (IO) is an anti-CD22 calicheamicin immunoconjugate that has been recently approved for the treatment of relapsed or refractory B-Acute Lymphoblastic Leukemia (r/r B-ALL). We employed both immortalized and primary cells derived from CD22-positive lymphoproliferative disorders to...

Full description

Bibliographic Details
Main Authors: Elena Tirrò, Michele Massimino, Chiara Romano, Maria Stella Pennisi, Stefania Stella, Silvia Rita Vitale, Annamaria Fidilio, Livia Manzella, Nunziatina Laura Parrinello, Fabio Stagno, Giuseppe Alberto Palumbo, Piera La Cava, Alessandra Romano, Francesco Di Raimondo, Paolo G. Vigneri
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
p53
inotuzumab ozogamicin
Chk1
B-ALL
antibody-drug conjugates
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00057/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00057/full

Similar Items